Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11-12
|
| pubmed:dateCreated |
1980-4-17
|
| pubmed:abstractText |
A phase I evaluation of a weekly schedule of anguidine was undertaken as an alternative to the present continuous daily schedules. The dose ranged from 1.5 to 7.5 mg/m2 given as an infusion over 3 hours. No myelosuppression was noted at any dose level. The toxic effects included nausea and vomiting, hypotension, CNS symptoms (confusion, hallucinations, and psychomotor seizures), chills, fever, and diarrhea. A dose of 5 mg/m2 of anguidine produced acceptable toxicity.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0361-5960
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
63
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2015-7
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:526934-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:526934-Brain,
pubmed-meshheading:526934-Drug Administration Schedule,
pubmed-meshheading:526934-Drug Evaluation,
pubmed-meshheading:526934-Fever,
pubmed-meshheading:526934-Humans,
pubmed-meshheading:526934-Hypotension,
pubmed-meshheading:526934-Infusions, Parenteral,
pubmed-meshheading:526934-Neoplasms,
pubmed-meshheading:526934-Sesquiterpenes,
pubmed-meshheading:526934-Trichothecenes,
pubmed-meshheading:526934-Vomiting
|
| pubmed:articleTitle |
Phase I evaluation of a weekly schedule of anguidine. Southeastern Cancer Study Group Committee on Gastrointestinal Malignancies.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.
|